NovaBay Pharmaceuticals Inc. [AMEX: NBY] surged by $0.15 during the normal trading session. The company report on February 8, 2021 that NovaBay CEO Issues Letter to Stockholders.
NovaBay Pharmaceuticals (NYSE American: NBY) issued the following Letter to Stockholders:.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
To My Fellow Stockholders:.
NovaBay Pharmaceuticals Inc. stock has also gained 19.33% of its value over the past 7 days. However, NBY stock has inclined by 148.43% in the 3 months of the year. Over the past six months meanwhile, it has gained 42.79% and gained 103.73% year-on date.
The market cap for NBY stock reached $66.75 million, with 40.04 million shares outstanding and 31.25 million shares in the current float. Compared to the average trading volume of 4.30M shares, NBY reached a trading volume of 23439140 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about NovaBay Pharmaceuticals Inc. [NBY]:
Ladenburg Thalmann have made an estimate for NovaBay Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 18, 2019. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on July 06, 2018, representing the official price target for NovaBay Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $10 to $8, while Laidlaw kept a Buy rating on NBY stock.
The Average True Range (ATR) for NovaBay Pharmaceuticals Inc. is set at 0.19, with the Price to Sales ratio for NBY stock in the period of the last 12 months amounting to 6.81. The Price to Book ratio for the last quarter was 4.06, with the Price to Cash per share for the same quarter was set at 0.29.
NBY stock trade performance evaluation
NovaBay Pharmaceuticals Inc. [NBY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 19.33. With this latest performance, NBY shares gained by 36.54% in over the last four-week period, additionally plugging by 42.79% over the last 6 months – not to mention a rise of 137.10% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NBY stock in for the last two-week period is set at 68.57, with the RSI for the last a single of trading hit 69.43, and the three-weeks RSI is set at 67.46 for NovaBay Pharmaceuticals Inc. [NBY]. The present Moving Average for the last 50 days of trading for this stock 0.9117, while it was recorded at 1.3380 for the last single week of trading, and 0.8929 for the last 200 days.
NovaBay Pharmaceuticals Inc. [NBY]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and NovaBay Pharmaceuticals Inc. [NBY] shares currently have an operating margin of -140.02 and a Gross Margin at +73.66. NovaBay Pharmaceuticals Inc.’s Net Margin is presently recorded at -146.79.
Return on Total Capital for NBY is now -185.30, given the latest momentum, and Return on Invested Capital for the company is -301.21. Return on Equity for this stock declined to -326.88, with Return on Assets sitting at -94.14. When it comes to the capital structure of this company, NovaBay Pharmaceuticals Inc. [NBY] has a Total Debt to Total Equity ratio set at 415.83. Additionally, NBY Total Debt to Total Capital is recorded at 80.61, with Total Debt to Total Assets ending up at 36.06. Long-Term Debt to Equity for the company is recorded at 51.90, with the Long-Term Debt to Total Capital now at 10.06.
Reflecting on the efficiency of the workforce at the company, NovaBay Pharmaceuticals Inc. [NBY] managed to generate an average of -$345,964 per employee. Receivables Turnover for the company is 2.89 with a Total Asset Turnover recorded at a value of 0.64.NovaBay Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.10 and a Current Ratio set at 5.30.
Earnings per share (EPS) analysis for NovaBay Pharmaceuticals Inc. [NBY] stock
With the latest financial reports released by the company, NovaBay Pharmaceuticals Inc. posted -0.13/share EPS, while the average EPS was predicted by analysts to be reported at -0.07/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -85.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NBY.
NovaBay Pharmaceuticals Inc. [NBY]: Insider Ownership positions
There are presently around $1 million, or 6.00% of NBY stock, in the hands of institutional investors. The top three institutional holders of NBY stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 400,393, which is approximately -34.686% of the company’s market cap and around 25.21% of the total institutional ownership; VANGUARD GROUP INC, holding 160,224 shares of the stock with an approximate value of $0.23 million in NBY stocks shares; and CITADEL ADVISORS LLC, currently with $0.12 million in NBY stock with ownership of nearly 271.699% of the company’s market capitalization.
Positions in NovaBay Pharmaceuticals Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 9 institutional holders increased their position in NovaBay Pharmaceuticals Inc. [AMEX:NBY] by around 227,018 shares. Additionally, 5 investors decreased positions by around 264,528 shares, while 11 investors held positions by with 546,689 shares. The mentioned changes placed institutional holdings at 1,038,235 shares, according to the latest SEC report filing. NBY stock had 5 new institutional investments in for a total of 145,324 shares, while 2 institutional investors sold positions of 42,551 shares during the same period.